Provectus Biopharmaceuticals, Inc. (PVCT) – Goodman & Nekvasil P.A. May Recover Investor Losses

Provectus Biopharmaceuticals, Inc. (PVCT) – Goodman & Nekvasil P.A. May Recover Investor Losses

Provectus Biopharmaceuticals, Inc. (PVCT) is a penny stock that, historically, has had no revenues from operation and yearly net losses. Gary Alan Meier, formerly a licensed broker with Symetra Investment Services and Cambridge Investment Research, sold a considerable amount of this penny stock to Gary Alan Meier’s clients, many of whom were elderly. Provectus Biopharmaceuticals, Inc.’s (PVCT) financial condition prompted Provectus Biopharmaceuticals, Inc.’s (PVCT) auditor to draft a going concern opinion (a going concern opinion means that there is substantial doubt that the company can continue as an ongoing business for the next 12 months). Provectus Biopharmaceuticals, Inc. (PVCT) has had less than five employees for a significant period of time. Provectus Biopharmaceuticals, Inc. (PVCT) recently settled a class action lawsuit alleging that the company made false statements relating to the development of its drug. Provectus Biopharmaceuticals, Inc.’s (PVCT) former CEO also recently resigned due to his theft of over $2,000,000 from the company from 2013 to 2015. If you purchased Provectus Biopharmaceuticals, Inc. (PVCT) from Gary Meier, our firm may be able to help you.

FINRA reports that the State of Washington filed an enforcement action against Gary Meier seeking to suspend Gary Meier’s securities license. The State of Washington alleged that Gary Meier made unsuitable investment recommendations of Provectus Biopharmaceuticals, Inc.  (PVCT) to Gary Meier’s clients, misrepresented and omitted material information about Provectus Biopharmaceuticals, Inc. (PVCT), and provided clients with grossly exaggerated future values of Provectus Biopharmaceuticals, Inc. (PVCT).

If you invested in Provectus Biopharmaceuticals, Inc. (PVCT), and you lost money, you may be able to recover your losses from Cambridge Investment Research, Inc. and/or Symetra Investment Services, Inc. This is because Cambridge Investment Research, Inc. and Symetra Investment Services, Inc. had a duty to supervise Gary Meier.

If you lost money on Provectus Biopharmaceuticals, Inc. (PVCT) stock, we would like to discuss the possibility of your retaining our firm to represent you in an arbitration action against Cambridge Investment Research, Inc. and/or Symetra Investment Services, Inc., concerning Gary Meier’s conduct. There is no charge for an evaluation of your case. Further, we handle our cases on a contingency fee basis. This means that unless we recover money for you, we charge no attorney’s fee. Unless you recover any money, you pay us nothing, not even the costs and expenses which the firm will advance on your behalf.

Kalju Nekvasil, Esq., formerly regional counsel with the NASD, now known as FINRA, has practiced in this area of the law for more than 35 years. Goodman & Nekvasil, P.A. has recovered more than $300 million on behalf of victimized investors. If you lost money on investments in Provectus Biopharmaceuticals, Inc. (PVCT) stock and would like your case evaluated by a securities attorney (again, there is no charge for an evaluation and all cases are handled on a purely contingency fee basis), please contact us.  


Keywords: PVCT, Provectus Biopharmaceuticals, Symetra Investment Services, Cambridge Investment Research, FINRA, SEC, Fraud, Attorney, Broker, Brokerage, Firm, Brokerage Firm, Invest, Lawyer, Securities Lawyer, Goodman and Nekvasil, Nekvasil, Goodman, Investor, Investment, Financial, Financial Services, Securities 


Contact Us Today!

1 Step 1
FormCraft - WordPress form builder